What Are Analysts Report About Progenics Pharmaceuticals, Inc. (PGNX)


Progenics Pharmaceuticals, Inc. (PGNX) will report its next earnings on May 04 BMO. The company reported the earnings of $-0.23/Share in the last quarter where the estimated EPS by analysts was $-0.19/share. The difference between the expected and actual EPS was $-0.04/share, which represents an Earnings surprise of -21.1%.

Many analysts are providing their Estimated Earnings analysis for Progenics Pharmaceuticals, Inc. and for the current quarter 4 analysts have projected that the stock could give an Average Earnings estimate of $-0.19/share. These analysts have also projected a Low Estimate of $-0.2/share and a High Estimate of $-0.17/share.

In case of Revenue Estimates, 4700 analysts have provided their consensus Average Revenue Estimates for Progenics Pharmaceuticals, Inc. as 4000. According to these analysts, the Low Revenue Estimate for Progenics Pharmaceuticals, Inc. is 3.4 Million and the High Revenue Estimate is 5.7 Million. The company had Year Ago Sales of 8.48 Million.

These analysts also forecasted Growth Estimates for the Current Quarter for PGNX to be -137.5%. They are projecting Next Quarter growth of -128.8%. For the next 5 years, Progenics Pharmaceuticals, Inc. is expecting Growth of 296.4% per annum, whereas in the past 5 years the growth was -16.22% per annum.

Some buy side analysts are also providing their Analysis on Progenics Pharmaceuticals, Inc., where 4 analysts have rated the stock as Strong buy, 1 analysts have given a Buy signal, 0 said it’s a HOLD, 0 reported it as Underperform and 0 analysts rated the stock as Sell. (These Recommendations are for the Current Month Only reported by Yahoo Finance.)

When it comes to the Analysis of a Stock, Price Target plays a vital role. Analysts reported that the Price Target for Progenics Pharmaceuticals, Inc. might touch $14 high while the Average Price Target and Low price Target is $13.6 and $12 respectively.

Progenics Pharmaceuticals, Inc. closed its last trading session at $6.43 with the gain of 8.4%. The Market Capitalization of the company stands at 562.13 Million. The Company has 52-week high of $11.72 and 52-week low of $4.00. The stock’s current distance from 20-Day Simple Moving Average (SMA20) is -12.22% where SMA50 and SMA200 are -27.28% and -12.79% respectively. The Company Touched its 52-Week High on 03/15/17 and 52-Week Low on 06/27/16.

The Relative Volume of the company is 1.57 and Average Volume (3 months) is 1.52 million. Progenics Pharmaceuticals, Inc. P/E (price to earnings) ratio is 44.68 and Forward P/E ratio of 72.6.

The company shows its Return on Assets (ROA) value of 0%. The Return on Equity (ROE) value stands at 0%. While it’s Return on Investment (ROI) value is 7.3%.

While looking at the Stock’s Performance, Progenics Pharmaceuticals, Inc. currently shows a Weekly Performance of -15.72%, where Monthly Performance is -18.29%, Quarterly performance is -30.3%, 6 Months performance is 41.67% and yearly performance percentage is 38.29%. Year to Date performance value (YTD perf) value is -19.33%. The Stock currently has a Weekly Volatility of 8.35% and Monthly Volatility of 5.00%.